Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-232411 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1A: AGN-232411 Dose A | EXPERIMENTAL | One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants. |
| Cohort 1B: AGN-232411 Dose B | EXPERIMENTAL | One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable. |
| Cohort 1C: AGN-232411 Dose C | EXPERIMENTAL | One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable. |
| Cohort 1: AGN-232411 Vehicle | PLACEBO_COMPARATOR | One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants. |
| Cohort 2A: AGN-232411 Dose A | EXPERIMENTAL | One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease. |
| Cohort 2B: AGN-232411 Dose B | EXPERIMENTAL | One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable. |
| Cohort 2C: AGN-232411 Dose C | EXPERIMENTAL | One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable. |
| Cohort 2: AGN-232411 Vehicle | PLACEBO_COMPARATOR | One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease. |
| Name | Type | Description |
|---|---|---|
| AGN-232411 | DRUG | AGN-232411 topical ophthalmic solution |
| AGN-232411 Vehicle | DRUG | Vehicle for AGN-232411 topical ophthalmic solution. |
Inclusion criteria: Stage 1 -Healthy participants. Stage 2 -Participants with the symptoms of dry eye disease. Exclusion criteria: Stage 1 -Known allergies or sensitivities to study medications, fluorescein, or lissamine green Stage 2 * Known allergies or sensitivities to study medications, ...
AGN-232411 is an investigational small molecule being developed by AbbVie Inc. for use in ophthalmology. It is being studied in healthy volunteers and in participants with dry eye syndromes, as part of a Phase 1 clinical trial.
AGN-232411 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV.
AGN-232411 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
AGN-232411 has been studied in one completed Phase 1 trial, identified as NCT02420730. This trial evaluated the safety, tolerability, and systemic pharmacokinetics of AGN-232411 in healthy participants and participants with dry eye.
No alternative names for AGN-232411 have been disclosed. It is identified solely by its code name AGN-232411 in clinical trial records.